.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers have developed a groundbreaking Roxithromycin detection biosensor that utilizes a target-induced DNA nanodevice. This system combines a regenerable Surface-Enhanced Raman Scattering (SERS) substrate with an advanced signal amplification strategy. Consequently, the sensor addresses common limitations such as substrate waste and poor detection stability. Additionally, the integration of these technologies ensures an ultrasensitive platform for clinical and pharmaceutical applications.
The core of this innovation involves the HOF@Au substrate, which researchers engineered by reducing gold nanoparticles on alkali-resistant HOF-102. Furthermore, the team designed a DNA triplex structure that responds directly to pH levels. When the target antibiotic is present, the specific aptamer activates a DNAzyme. This interaction triggers a series of cleavage and rolling-assembly cycles. Therefore, this cascade system amplifies the Raman signal significantly. This mechanism allows for the precise quantification of trace drug levels in various samples.
The proposed strategy demonstrates a remarkable limit of detection at 3.97 × 10-14 mol/L. Notably, the system is fully regenerable due to the pH-responsive nature of the DNA structure. By modulating pH, the triplex structure folds or unfolds to allow for the efficient reuse of the SERS substrate. This capability simplifies testing procedures while significantly reducing overall laboratory costs. As a result, this multifunctional platform offers a sustainable model for the future of antibiotic monitoring and biosensing.
The HOF@Au substrate provides a uniform and high-enhancement surface for Raman signals. It is alkali-resistant and regenerable, which makes the detection process more stable and cost-effective than traditional single-use substrates.
The nanodevice uses a target-triggered cycling mechanism involving identifying, cleaving, and rolling-assembly steps. This cascade system amplifies the SERS signal, enabling the sensor to detect trace concentrations of Roxithromycin as low as 3.97 × 10-14 mol/L.
Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new HOF@Au SERS biosensor with a DNA nanodevice enables ultrasensitive, regenerable detection of Roxithromycin with a detection limit of 3.97 × 10⁻¹⁴ mol/...
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
